NCT05266274

Clinical Efficacy and Safety of CD47 Monoclonal Antibody Combined With Azacitidine in the Treatment of Recurrent AML After Transplantation

A Single-center, Single-arm Clinical Study of the Clinical Efficacy and Safety of CD47 Monoclonal Antibody Combined With Azacitidine in the Treatment of Recurrent AML After Transplantation

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 69 (estimated)
• Sponsor: The First Affiliated Hospital of Soochow University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

After screening according to the criteria for selection and exclusion, patients who meet the criteria are selected, CD47 monoclonal antibody combined with azacitidine is used for the treatment of patients with recurrent AML after transplantation. The primary outcome is objective response rate (ORR).

Conditions

• Patients With Recurrent Acute Myelogenous Leukemia After Transplantation

Interventions

Type	Name	Description
DRUG	CD47 monoclonal antibody	patients who meet the criteria are selected, CD47 monoclonal antibody combined with azacitidine is used for the treatment of patients with recurrent AML after transplantation

Timeline

• Start date: 2021-12-14
• Primary completion: 2023-06-30
• Completion: 2023-12-31
• First posted: 2022-03-04
• Last updated: 2022-03-04

Locations

1 site across 1 country: China